Groups
Company Size (Fulltime employees)
Partnering Objectives
Functionality
Headquartner in China
Biotech/Pharma Category
Biotech/Pharma Asset Stage
Medtech Category
Medtech Development Stage
Index
Countries
Reset

J. Gene WANG United States

Immetas discovers and develops novel therapeutics that modulate the innate immune system to treat age-related cancers and inflammatory diseases. The company’s approach is based on emerging evidence that chronic low-grade inflammation is a fundamental process governing aging and age-related diseases, and anchored in clinical evidence to mitigate development risk. Immetas was founded by J. Gene Wang, MD, PhD, a veteran in discovery and translational drug development in immunology/ inflammation and oncology, and David Sinclair, PhD, Professor of Genetics at Harvard Medical School and a leader in the molecular mechanisms of aging. The lead program in the company’s growing pipeline is focused on engineering bispecific antibodies to modulate inflammation in the tumor microenvironment and overcome resistance to the conventional immune checkpoint therapies. Learn more at www.immetas.com
Website:
https://immetas.com/
Partnering Objectives
Headquartner in China
No
Immetas Therapeutics
CEO 

Cynthia Wang China

.
Website:
www.Servier.com
Company Size (Fulltime employees)
1-10
Partnering Objectives
Please specify your partnering goal
Assets based licensing in
Headquartner in China
No
Servier
BD&Licensing Director 

Dr. Duan Wang China

Hengrui is the largest pharmaceutical company based in China by market cap (around 90 billion USD) and among the top ones by revenue and R&D spending (3.28b USD and 549m USD in 2019, respectively). 5+ differentiated products in global clinical development with commercial rights available for discussions.
Website:
http://www.hrs.com.cn/
Company Size (Fulltime employees)
5000+
Partnering Objectives
Please specify your partnering goal
Looking for Assets to in license and global partners
Headquartner in China
Yes
Biotech/Pharma Category
Assets Information 1
SHR-1701|SHR-1701is an anti-PD-L1/TGF-βRII bi-functional fusion protein that inhibits PD-L1 andTGF-β. It is currently under phase II and phase I clinical development in China and Australia, respectively. Preliminary data from SHR-1701’s two phase I trials showed promising efficacy and safety.|Solid tumor|
Assets Information 2
Pyrotinib|Pyrotinib is a novel selective tyrosine kinase inhibitor of EGFR/HER2/HER4, with superior efficacy vs. lapatinib. Global registrational trial ongoing; approved in China.|HER2-positive breast cancer|
Assets Information 3
Fluzoparib|Fluzoparib is a PARP inhibitor to address ovarian cancer, breast cancer, prostate cancer, pancreatic cancer, and other advanced solid tumors.|Solid tumor|
Biotech/Pharma Asset Stage
Jiangsu Hengrui Pharma
Associate Director of BD 
Functionality
Business Development

Jonathan Wang

Inmagene Biopharmaceuticals
Chairman and CEO 

grace wang China

DENTAL MATERIALS
STENTS
EPIDEMIC PREVENTION PRODUCTS ETC.
Website:
www.atmbio.com
Partnering Objectives
Headquartner in China
Yes
Beijing ATMbiomaterials Co., Ltd
MD 

Dr. Zongxing Wang United States

VC in Chicago
Website:
https://www.archventure.com/
Company Size (Fulltime employees)
1-10
Partnering Objectives
Please specify your partnering goal
just check out
Headquartner in China
No
ARCH Venture Partners
Investor 

Ms Luyao Wang China

Website:
www.jacobiopharma.com
Company Size (Fulltime employees)
51-200
Year of foundation
5
Biotech/Pharma Category
Jacobio Pharmaceuticals
Director of PR 
Functionality
Other

Dr. Tianke Wang Switzerland

Dao Tun is a consulting company, founded in 2019, specialised in cross-border collaboration between Europe and China, primarily in the healthcare and life science industry.
Dao Tun is based in the Basel region, one of the world's leading clusters for Pharma and Life Sciences and also part of the trinational Biovalley region (Switzerland, Germany, France).
Dao Tun team provides customised strategy and execution plan via in-depth interview and targeted research; quickly gains insights into the association and matching between potential partners to make accurate and effective connections; simplifies the processes, reduces the cost of communication, and establishes the trust with full care.
Dao Tun is a bridge builder who excels at understanding and interpreting their interests and needs, and aligning perspectives of different stakeholders and across cultures for win-win-win situation.

Website:
www.dao-tun.ch
Company Size (Fulltime employees)
1-10
Year of foundation
2019
Partnering Objectives
Please specify your partnering goal
looking for clients and partners who have interest to enter Chinese market for fundraising, licensing, partnering etc.
Headquartner in China
No
Biotech/Pharma Category
Medtech Category
Dr. Tianke Wang
Dao Tun GmbH
CEO 
Functionality
Management

William Wang China

Pls check us at company website.
Website:
www.tiandapharma.com
Partnering Objectives
Headquartner in China
Yes
Tianda Pharmaceutical Ltd
EVP 

Dr. Weiqing Wang China

AnHeart Therapeutics is an oncology-focused clinical stage biopharmaceutical company headquartered in Hangzhou, China with offices in Beijing, Shanghai and New York. The company’s pipeline consists of three clinical stage assets: Taletrectinib, a next-gen ROS1 and NTRK inhibitor currently in Phase 2; an mIDH1 inhibitor ready for Phase 2 for low grade glioma, cholangiocarcinoma, AML and other tumors; and an AXL inhibitor in Phase 1 for overcoming resistance in various tumors.
Website:
http://anhearttherapeutics.com/en/home/
Company Size (Fulltime employees)
11-50
Year of foundation
2018
Partnering Objectives
Please specify your partnering goal
1/Funding Raising for Series B; 2/Pipeline Asset EU and Korea out licensing; 3/In licensing new clinical PoC oncology assets
Headquartner in China
Yes
Biotech/Pharma Category
Assets Information 1
Taletrectinib|next-gen ROS1/NTRK inhibitor, the leading program, currently in a Phase 2 trial in China and ex-China global trials to start in early 2021|ROS1+ NSCLC|Global
Assets Information 2
AB-218/DS-1001|a potentially best-in-class mIDH-1 inhibitor in co-development with Daiichi Sankyo (Japan rights), to start with ex-Japan global Phase 2 trials in glioma and conduct preclinical and clinical POC studies in other indications|IDH1+ Lower Grade Glioma|ex-Japan
Assets Information 3
AB-329/DS-1205|a potentially best-in-class AXL inhibitor, to start with preclinical and clinical POC studies in multiple indications|combo with PD-1 ab for NSCLC|Global
Biotech/Pharma Asset Stage
AnHeart Therapeutics
Associate Director of BD 
Functionality
Business Development